Sign in   |   Register
HOME MARKET NEWS CENTRE ECONOMY RESEARCH MUTUAL FUNDS FINANCIAL PLANNING INSURANCE BUDGET ABOUT US F&O IPO Commodities Stock-Screener Get NAV Snapshot Portfolio Dividends News Interviews Charts 06 July, 2025 18:33 IST Get Quote Snapshot Charts Financials Research News iWealth Tracker Newsletter Tax Corner Financial Health Check Expert Speak Feedback Follow @myirisdotcom

Cipla gets final nod for Lanreotide Injection Source: IRIS | 20 Dec, 2021, 04.51PM Rating: NAN / 5 stars. Comments  |  Post Comment Notice: Undefined variable: fileR in /me/beta.myiris.com/htdocs/newsCentre/bin/addLinksNew.php on line 17 Notice: Undefined variable: fileR in /me/beta.myiris.com/htdocs/newsCentre/bin/addLinksNew.php on line 142 Cipla, a leading drug maker, announced that the company has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL singledose pre-filled syringes. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). Umang Vohra (MD and Global CEO, Cipla) said, "We are pleased to receive the final approval for Lanreotide injection from the USFDA. Enabling access to high-quality treatments is core to our purpose of "Caring for Life". This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipeline and address unmet patient needs. The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT, from Ipsen Biopharmaceuticals Inc. According to IQVIA, SOMATULINE DEPOT had US sales of approximately USD 867 million for the 12-month period ending October 2021. Shares of the company gained Rs 34.75, or 4.04%, to trade at Rs 894.60. The total volume of shares traded was 190,460 at the BSE (3.17 p.m, Monday).  Post Comment Notice: Undefined index: dir in /me/beta.myiris.com/htdocs/newsCentre/comments.php on line 162 > Name Email Comment Security Code type    Notice: Undefined variable: captchacode in /me/beta.myiris.com/htdocs/newsCentre/comments.php on line 183 into this box

Related Articles

Notice: Constant DOC_ROOT_FOR_HTML_FILES already defined in /me/beta.myiris.com/htdocs/newsCentre/rightSideTabs.php on line 1 Most Read Expert Speak 22-09-16 Sensex surges over 300 points as US Federal Reserve holds rate 22-09-16 Sensex gains 281 points; Nifty trades at 8,862-level 22-09-16 Rupee appreciates 18 paise against dollar in early trade 22-09-16 Edelweiss Group to acquire Ambit Alpha Fund more... more...

Notice: Undefined index: secID in /me/beta.myiris.com/htdocs/newsCentre/storyShow.php on line 470 Notice: Undefined index: secID in /me/beta.myiris.com/htdocs/newsCentre/storyShow.php on line 470

Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise © All rights reserved. IRIS Business Services Limited A Disclaimer

Warning: fopen(/me/beta.myiris.com/htdocs/newsCentre/news_web_count.txt): failed to open stream: Permission denied in /me/beta.myiris.com/htdocs/newsCentre/storyShow.php on line 566

Warning: fwrite() expects parameter 1 to be resource, boolean given in /me/beta.myiris.com/htdocs/newsCentre/storyShow.php on line 567

Warning: fclose() expects parameter 1 to be resource, boolean given in /me/beta.myiris.com/htdocs/newsCentre/storyShow.php on line 568

Notice: Undefined index: key in /me/beta.myiris.com/htdocs/newsCentre/storyShow.php on line 571